Evidence map›Paper›PMID 41852580›Full record

ArticleBiotechnology reports (Amsterdam, Netherlands)2026

Comparative analysis of anti-MICA scFv affinities: Insights from three label-free biophysical methods and biological validation.

Karen Toledo-Stuardo, Nicolás Fehring, Homero Gómez-Velasco, Rodrigo Sierpe, Daniel Guerra, Douglas J Matthies, Yuneisy Guerra, Fabiola González-Herrera, Mauricio González, Ivo Campos and 13 more

Abstract read
In one paragraph

Article in Biotechnology reports (Amsterdam, Netherlands), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Karen Toledo-StuardoNúcleo Interdisciplinario de Farmacología e Inmunología, Instituto de Ciencias Biomédicas (ICBM), Facultad de Medicina, Universidad de Chile, Santiago, Chile.
Nicolás FehringNúcleo Interdisciplinario de Farmacología e Inmunología, Instituto de Ciencias Biomédicas (ICBM), Facultad de Medicina, Universidad de Chile, Santiago, Chile.
Homero Gómez-VelascoInstituto de Química, Universidad Nacional Autónoma de México, Ciudad Universitaria, Ciudad de México, México.
Rodrigo SierpeDepartamento de Química Farmacológica y Toxicológica, Facultad de Ciencias Químicas y Farmacéuticas, Universidad de Chile, Santiago, Chile.
Daniel GuerraDepartamento de Química, Facultad de Ciencias, Universidad de Chile, Santiago, Chile.
Douglas J MatthiesNúcleo Interdisciplinario de Farmacología e Inmunología, Instituto de Ciencias Biomédicas (ICBM), Facultad de Medicina, Universidad de Chile, Santiago, Chile.
Yuneisy GuerraNúcleo Interdisciplinario de Farmacología e Inmunología, Instituto de Ciencias Biomédicas (ICBM), Facultad de Medicina, Universidad de Chile, Santiago, Chile.
Fabiola González-HerreraNúcleo Interdisciplinario de Farmacología e Inmunología, Instituto de Ciencias Biomédicas (ICBM), Facultad de Medicina, Universidad de Chile, Santiago, Chile.
Mauricio GonzálezNúcleo Interdisciplinario de Farmacología e Inmunología, Instituto de Ciencias Biomédicas (ICBM), Facultad de Medicina, Universidad de Chile, Santiago, Chile.
Ivo CamposNúcleo Interdisciplinario de Farmacología e Inmunología, Instituto de Ciencias Biomédicas (ICBM), Facultad de Medicina, Universidad de Chile, Santiago, Chile.
Samantha TelloNúcleo Interdisciplinario de Farmacología e Inmunología, Instituto de Ciencias Biomédicas (ICBM), Facultad de Medicina, Universidad de Chile, Santiago, Chile.
María José GarridoNúcleo Interdisciplinario de Farmacología e Inmunología, Instituto de Ciencias Biomédicas (ICBM), Facultad de Medicina, Universidad de Chile, Santiago, Chile.
Gonzalo VásquezEscuela de Ingeniería Bioquímica, Pontificia Universidad Católica de Valparaíso, Valparaíso, Chile.
Jose Rodríguez-SizaEscuela de Ingeniería Bioquímica, Pontificia Universidad Católica de Valparaíso, Valparaíso, Chile.
Mauricio VergaraEscuela de Ingeniería Bioquímica, Pontificia Universidad Católica de Valparaíso, Valparaíso, Chile.
Carolina H RibeiroNúcleo Interdisciplinario de Farmacología e Inmunología, Instituto de Ciencias Biomédicas (ICBM), Facultad de Medicina, Universidad de Chile, Santiago, Chile.
Gerald Zapata-TorresCentro de Moledamiento Molecular, Biofísica y Bioinformática (CM2B2), Facultad de Ciencias Químicas y Farmacéuticas, Universidad de Chile, Santiago, Chile.
Soledad BolloDepartamento de Química Farmacológica y Toxicológica, Facultad de Ciencias Químicas y Farmacéuticas, Universidad de Chile, Santiago, Chile.
Enrique García-HernándezInstituto de Química, Universidad Nacional Autónoma de México, Ciudad Universitaria, Ciudad de México, México.
Denis FuentealbaFacultad de Química y de Farmacia, Pontificia Universidad Católica de Chile, Santiago, Chile.
Norma A Valdez-CruzCentro de Nanociencias y Nanotecnología, Universidad Nacional Autónoma de México, Ensenada, B.C., México.
Claudia AltamiranoEscuela de Ingeniería Bioquímica, Pontificia Universidad Católica de Valparaíso, Valparaíso, Chile.
María Carmen MolinaNúcleo Interdisciplinario de Farmacología e Inmunología, Instituto de Ciencias Biomédicas (ICBM), Facultad de Medicina, Universidad de Chile, Santiago, Chile.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antibody-antigen affinity is a key factor in the development of therapeutic antibodies, influencing candidate selection and their clinical efficacy. We used a combination of three label-free biophysical techniques: SPR, ITC, and fluorescence quenching, to rank anti-MICA single-chain variable fragments (scFvs), complemented by ELISA. We evaluated a wild-type (WT) scFv and its Beta mutant across the platforms, complementing this with molecular dynamics simulations and functional assays. The affinity constants (K

Indexed as

AffinityAntibodyMICASingle-chain variable fragment (scFv)SPR

Identifiers

PMID41852580
PMCPMC12991960

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.